Pasithea Reports Substantial Tumor Shrinkage With PAS-004 in Early NF1 Study, FDA Clears Phase 2
Early results show PAS-004 reduced neurofibroma size in all evaluated NF1 patients.
Early results show PAS-004 reduced neurofibroma size in all evaluated NF1 patients.
New FDA clearance lets Tandem Mobi users go tubeless for up to 7 days while keeping Control-IQ+ technology. Launch expected in early 2027.
Wells Fargo initiates Alector with an Overweight rating and $7 price target, citing its brain carrier platform and Alzheimer’s drug AL-137.
Final European Commission decision pending.
Moderna guided for 15–25% revenue growth in 2026 and said cash costs will rise to approximately $4 billion in 2027, remaining elevated through 2030.
China approved Eli Lilly’s orforglipron pill for weight loss, giving it an early lead over Novo Nordisk in the world’s second-largest drug market.
Oppenheimer says Capricor’s Q3 update shows strong support for deramiocel in Duchenne. FDA decision expected around Nov 22; stock could hit $50.
Analyst Ryan Deschner lifted Liquidia’s rating and price target to $77, citing robust PAH demand, rising shipments, and resolved litigation with United Therapeutics.
Phase 2 FREEDOM2 results for PGN-EDODM1 deliver 46.5% mean splicing correction, functional improvements, and strong analyst support.
Analysts upgraded Zentalis after DENALI Part 1b data showed median survival of 15.9 months in Cyclin E1-positive platinum-resistant ovarian cancer.
Hims & Hers stock drops after missing revenue and subscriber expectations. Q3 revenue rose 49% to $890M, but margins compressed and guidance tightened.
The biotech’s initial JANX011 Phase 1 results in healthy volunteers triggered a sharp selloff as investors questioned near-term value and differentiation.
Foundayo cut breathing interruptions by as much as 43.8% in a late-stage sleep apnea trial, supporting a new major market for Lilly.
Shares of Abeona Therapeutics plunged after the company issued new stock for a Phase 3 EoE candidate and completed a $30 million PIPE.
Shares of Faeth Therapeutics plunged after Phase 2 endometrial cancer data hit the expected bar but failed to drive a re-rating of the stock.
CorMedix agrees to buy Heron Therapeutics’ assets, including ZYNRELEF, APONVIE, CINVANTI and SUSTOL, with $145M cash plus stock. Closing expected in Q1 2027.
Zura Bio shares plunged after its Phase 2 TibuSHIELD trial of tibulizumab in hidradenitis suppurativa failed to meet primary and key secondary endpoints.
The acquisition adds Frontage’s clinical bioanalysis expertise and strengthens Charles River’s drug development offering.
Early data show 70% two-year survival with brenetafusp plus KIMMTRAK in first-line metastatic uveal melanoma. Median OS not reached after 29 months.
Reports of a potential sale process lifted Edgewise Therapeutics (EWTX) shares, with multiple pharmaceutical companies said to be involved.
Moderna lifted its 2026 revenue growth forecast to 15–25% after strong international COVID vaccine sales helped it return to profit in Q3.
Lilly partners with Hims & Hers so patients can access Zepbound ($299/mo) and Foundayo ($149/mo) at self-pay prices on the telehealth platform.
Report cites competition and prior 95% decline after 2021 peak.
ANIP announced a public offer to acquire Egetis Therapeutics, bringing in EMCITATE, the first approved treatment for MCT8 deficiency.
The non-binding bid values the rare obesity drugmaker at up to $134 a share.
William Blair says updated ASH abstract data for Cullinan’s CLN-049 show lower response rates, sending shares down. Analyst keeps Outperform.
CVS Health reported Q3 adjusted EPS of $2.09, topping estimates, and raised full-year guidance to at least $8.20 as it plans to split into two companies by 2028.
Strong Wegovy pill sales helped Novo Nordisk beat forecasts and lift its full-year 2026 sales and profit guidance for the third time.
Sanofi has terminated the SAR448272 STAT6 degrader program. Nurix shares fell sharply in after-hours trading, but cash runway remains intact through 2029.
Usona’s potential FDA filing for psilocybin makes the competitive landscape more real for Compass, Definium, Helus Pharma and GH Research, analyst says.
RBC calls Krystal’s Q3 mixed. Vyjuvek beat expectations, but key pipeline readouts for DEB and CF now slip into 2027. Outperform, $400 PT.
Karyopharm has filed for Chapter 11 to pursue a merger with Ayrmid, securing $55 million in financing while continuing myeloma and myelofibrosis programs.
After earlier setbacks, FDA grants Priority Review to uniQure’s AMT-130 as a potential first disease-modifying Huntington’s treatment.
Bright Minds says FDA partial hold on its BMB-101 DEE study is limited to the planned U.S. trial and does not affect other programs.
INOVIO’s VOCERYQ receives FDA accelerated approval as the first DNA medicine in the US, reducing surgery frequency in adults with recurrent respiratory papillomatosis.
AstraZeneca posted solid 9M and Q3 results, beat forecasts, and launched a $1.5bn savings plan to fund its pipeline.
FDA pushed back the mitapivat SCD decision to Feb 2027 after a major amendment. Agios stock dropped on the delay.
The company will cease development of the drug and conserve cash after missing clinical endpoints.
Under new CEO Garijo, Sanofi says it may pursue larger acquisitions while lifting 2026 growth targets after strong Dupixent-led Q3 results.
Revenue grew 36% and non-GAAP EPS rose 70% on record Dupixent and EYLEA HD sales.
Iovance stock plunged on flat 24.6% response rates in its lung cancer trial, despite stronger results in a biomarker subgroup.
TTR franchise powers Alnylam’s Q3 results. Analysts cite decelerating Amvuttra growth and minor catalyst delays; Stifel cuts to Hold.
Merck beat Q3 forecasts with $18.1B sales and $2.49 EPS. Keytruda and Gardasil powered results as the company raised its full-year outlook.
Eli Lilly lifted its full-year revenue forecast to as much as $92 billion after strong Q3 sales of Mounjaro and Zepbound beat estimates, while trimming profit guidance on deal charges.
Hims & Hers shares rose after HHS said it will temporarily allow compounding pharmacies to produce six popular peptides, including BPC-157, while regulators review formal approval.
Phase 3 trial shows petosemtamab plus Keytruda halves risk of death versus Keytruda alone in first-line PD-L1+ recurrent/metastatic HNSCC.
FDA accepts Palvella’s QTORIN rapamycin NDA with Priority Review for microcystic lymphatic malformations. Target decision date is February 28, 2027.
Mineralys Therapeutics shares gained in premarket after Phase 2 Explore-CKD results for lorundrostat were published, showing significant blood pressure and albuminuria reductions.
GSK beat Q3 sales and profit forecasts on strong specialty medicines, but shares fell as investors questioned the pipeline and restructuring.
Artiva Biotherapeutics stops development of its autoimmune NK cell therapy AlloNK and cuts 94% of staff after two patient deaths and poor durability data.
Oruka’s ORKA-001 outperformed Skyrizi on complete clearance in Phase 2b. Analysts model $7B peak sales and maintain bullish ratings.
ArriVent BioPharma stock dropped sharply on Oct. 26 as investors questioned the confirmed response rate in early ARR-217 Phase 1 data for GI cancers.
Oric shares declined after Johnson & Johnson reported a 75% tumor response rate with JNJ-6143 in heavily pretreated advanced prostate cancer patients.
RBC Capital downgrades Perspective Therapeutics to Sector Perform and cuts its price target to $4 after VMT-α-NET Phase 1/2a results.
Positive Phase 2 data suggest Lifyorli plus chemotherapy and bevacizumab may offer meaningful benefit in hard-to-treat platinum-resistant ovarian cancer.
Xencor selected a Phase 3 dose for XmAb819 after early data showed strong responses in heavily pretreated advanced clear cell kidney cancer patients.
HealthSpan Partners will acquire Surgery Partners for $23.50 per share in a $5.7B deal. Bain Capital rolls its stake. Close expected Q1 2027.
Rina-S shows significant PFS and OS gains in platinum-resistant ovarian cancer, challenging Corcept’s Lifyorli position.
A patient with highly active relapsing MS died 44 days after receiving BMS’s experimental CD19 CAR-T therapy zola-cel in an early-stage trial.
Bolt Biotherapeutics merges with Prana Therapies in a $120 million deal to advance PRA-216 through Phase 2 trials in asthma, COPD, and atopic dermatitis.
AbbVie’s Phase 3 HS data fell short of expectations, prompting two firms to downgrade Avalo Therapeutics and lower confidence in IL-1 approaches.
Shares of Aardvark Therapeutics dropped after limited HERO data showed only temporary benefit for ARD-101 in Prader-Willi syndrome, delaying restart to 2027.
BDR Pharmaceuticals has sued the FDA over its decision to extend VOQUEZNA’s new chemical entity exclusivity through May 2032 under the GAIN Act.
Updated Phase 1/2 data at ESMO showed 82% ORR and 88% 9-month PFS with vopimetostat plus daraxonrasib in previously treated MTAP-deleted RAS-mutant PDAC.
Analysts see attractive risk/reward in Camp4’s SYNGAP1 program, Benitec’s gene therapy, Immunic’s MS trials, Pharvaris and Microbot’s robotic system.
Roche is paying Zymeworks $55M upfront for ZW209, a trispecific antibody designed to improve on Amgen’s Imdelltra in small-cell lung cancer.
Evaxion stock up on durable three-year EVX-01 results in melanoma. Immune hit rate reached 89%, but only 6 patients continued on monotherapy.
The FDA lifted the clinical hold on ARD-101, allowing Aardvark Therapeutics to resume development for Prader-Willi Syndrome after cardiac safety studies.
TD Cowen calls Phase 3 intismeran + Keytruda results “compelling” and in the exceptional range. Wells Fargo says RFS exceeded expectations.
Biohaven’s Vyglxia resubmission for SCA accepted for review by the FDA. Target action date is the first quarter of 2027.
EQT is offering €46.50 per share for Qiagen, a 40.3% premium to the unaffected price.
Positive CLARITY Phase 3 data for brepocitinib in uveitis lifts Roivant stock. Median time to treatment failure exceeded 48 weeks.
Abbott will separate its Nutrition unit into an independent company by 2027 and lowered its 2026 sales growth outlook to about 6%.
Ionis’s bepirovirsen (Hibsago) is now FDA-approved for chronic hepatitis B. The six-month treatment achieved functional cure in up to 26% of patients, far above standard care.
EQT has submitted a binding offer of more than $50 per share for Qiagen in a potential $10 billion takeover. KKR has also bid as shares jump.
Fresh ARC-20 data from Arcus show strong PFS and OS for casdatifan in first-, second- and late-line clear cell kidney cancer, per Mizuho.
Citrini’s Claude Science experiment shows AI can design protein binders in days, shifting the bottleneck to real labs and lifting demand for Charles River and Revvity.
Amgen and AstraZeneca’s Tezspire showed high histologic remission and symptom improvement in Phase 3 EoE trial, positioning it as a potential Dupixent rival.
Myriad Genetics agrees to sell its Prenatal Health testing business, including Prequel and Foresight, to Labcorp for $210 million, closing by early 2027.
Rapport’s RAP-219 hit key YMRS endpoints in bipolar mania, but agitation imbalance and higher dropouts may cap stock upside, per Wells Fargo.
FDA grants accelerated approval to Jemperli for stage II/III MSI-H/dMMR rectal cancer, sending AnaptysBio stock higher on royalty potential.
The deal adds siRNA technology and closes in Q1 2027.
Following a second Phase 3 miss for Duravyu in wet AMD, EyePoint will cut more than half its workforce, end the wet AMD studies early, and focus resources on its DME program.
Disc Medicine’s bitopertin succeeded on all primary and secondary endpoints in the APOLLO Phase 3 trial, sending the stock sharply higher.
The drug remains approved for other kidney diseases.
Positive REMAIN-1 data failed to support Fractyl’s valuation. Shares halved on modest effect size, cash runway, and remaining risks.
European regulators confirmed a negative opinion on Omeros’ first-in-class TA-TMA therapy despite FDA approval and strong U.S. demand.
Analyst sees approvable assets and places stock on Positive Catalyst Watch.
Labcorp will buy select BioReference clinical, women’s health, and urology assets from OPKO Health for up to $872 million, adding 80+ patient service centers.
LUCENT-2 and VIVID-1 post-hoc data show Omvoh enabled comprehensive disease control and corticosteroid-free deep remission in IBD at one year.
Recursion announces oversubscribed $200M raise, positive Phase 1b/2 FAP data for REC-4881, early REC-1245 activity, and Sanofi option milestone.
Landmark NEJM study shows Dexcom G7 reduces A1C and boosts time in range for non-insulin Type 2 diabetes patients, lifting shares.
VK2735 shows rapid weight loss in Phase 2, with financing through 2027.
The program is now on hold.
Eli Lilly, Merck, AbbVie, and UnitedHealth rose as markets fell on stronger inflation data, highlighting healthcare’s defensive strength.
FDA broadens Anktiva approval to papillary-only bladder cancer, giving ImmunityBio (IBRX) a larger addressable market in BCG-unresponsive NMIBC.
Vir Biotechnology and Gilead partner on dual-masked T-cell engagers for solid tumors in a deal worth up to $1.9B, as Vir’s CEO sees more partnership opportunities.
Verastem reports 50% confirmed response rate in second-line pancreatic cancer with VS-7375 and prices a $250 million stock offering.
YUTREPIA remains on the market for pulmonary arterial hypertension.
Generate Biomedicines receives $30M upfront in a deal with Zealand Pharma to advance AI protein candidates for obesity, up to $1.2B total.